(5) It has no known adverse effects.
The device we use, the Urogold 100 MTS, is a device deemed to have a non-significant risk to humans. In a phase 2 study, Patel et al ( Sex Med-uk 8, 214–222, 2020
) investigated the safety of LiST. They randomized patients into two Groups. Group A received once a day treatment over 5 consecutive days (Monday to Friday), in which 720 shocks of LiST were applied in every session, half to each treated region (left and right corpora cavernosa and crura). Group B consisted of once a day 3 sessions per week (Monday, Wednesday, and Friday) for 2 consecutive weeks, in which 600 shocks of LiST were applied. No immediate side effects of erythema, pain, or swelling have been noted with LiST treatment. In this same study no scar, plaque, or penile deformity was noted at six to 12 months.